Show simple item record

dc.contributor.authorCaballero Cuenca, Unai
dc.contributor.authorKim, Sarah
dc.contributor.authorEraso Barrio, María Elena ORCID
dc.contributor.authorQuindós Andrés, Guillermo
dc.contributor.authorVozmediano, Valvanera
dc.contributor.authorSchmidt, Stephan
dc.contributor.authorJauregizar Albonigamayor, Nerea ORCID
dc.date.accessioned2021-04-27T09:47:17Z
dc.date.available2021-04-27T09:47:17Z
dc.date.issued2021-03-28
dc.identifier.citationAntibiotics 10(4) : (2021) // Article ID 355es_ES
dc.identifier.issn2079-6382
dc.identifier.urihttp://hdl.handle.net/10810/51195
dc.description.abstractCandida auris is an emergent fungal pathogen that causes severe infectious outbreaks globally. The public health concern when dealing with this pathogen is mainly due to reduced susceptibility to current antifungal drugs. A valuable alternative to overcome this problem is to investigate the efficacy of combination therapy. The aim of this study was to determine the in vitro interactions of isavuconazole with echinocandins against C. auris. Interactions were determined using a checkerboard method, and absorbance data were analyzed with different approaches: the fractional inhibitory concentration index (FICI), Greco universal response surface approach, and Bliss interaction model. All models were in accordance and showed that combinations of isavuconazole with echinocandins resulted in an overall synergistic interaction. A wide range of concentrations within the therapeutic range were selected to perform time-kill curves. These confirmed that isavuconazole–echinocandin combinations were more effective than monotherapy regimens. Synergism and fungistatic activity were achieved with combinations that included isavuconazole in low concentrations (≥0.125 mg/L) and ≥1 mg/L of echinocandin. Time-kill curves revealed that once synergy was achieved, combinations of higher drug concentrations did not improve the antifungal activity. This work launches promising results regarding the combination of isavuconazole with echinocandins for the treatment of C. auris infections.es_ES
dc.description.sponsorshipThis research was funded by Consejería de Educación, Universidades e Investigación of Gobierno Vasco-Eusko Jaurlaritza, GIC15/78 IT-990-16 and by FIS, Spain, PI17/01538. UC was funded by a Ph.D. grant from the University of the Basque Country UPV/EHU, PIF 17/266.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.subjectcandida aurises_ES
dc.subjectcheckerboardes_ES
dc.subjectcombinationes_ES
dc.subjectantifungal agentses_ES
dc.subjectisavuconazolees_ES
dc.subjectechinocandinses_ES
dc.subjecttime-killes_ES
dc.titleIn Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida aurises_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2021-04-23T13:31:22Z
dc.rights.holder2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/2079-6382/10/4/355/htmes_ES
dc.identifier.doi10.3390/antibiotics10040355
dc.departamentoesFarmacología
dc.departamentoesInmunología, microbiología y parasitología
dc.departamentoeuFarmakologia
dc.departamentoeuImmunologia, mikrobiologia eta parasitologia


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).